These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33393509)

  • 21. Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma.
    Al-Batran SE; Rafiyan MR; Atmaca A; Neumann A; Karbach J; Bender A; Weidmann E; Altmannsberger HM; Knuth A; Jäger E
    Cancer Res; 2005 May; 65(9):3937-41. PubMed ID: 15867394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells.
    Kobayashi H; Kimura S; Aoki N; Sato K; Celis E; Katagiri M
    Immunogenetics; 2001 Oct; 53(8):626-33. PubMed ID: 11797095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions.
    Kang W; Sung PS; Park SH; Yoon S; Chang DY; Kim S; Han KH; Kim JK; Rehermann B; Chwae YJ; Shin EC
    Gastroenterology; 2014 May; 146(5):1351-60.e1-4. PubMed ID: 24486950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
    Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
    Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
    Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
    J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between major histocompatibility complex class I molecules and CD8+ T lymphocytes in prostate, and quantification of CD8 and interferon-gamma mRNA in prostate tissue specimens.
    Naoe M; Marumoto Y; Ishizaki R; Ogawa Y; Nakagami Y; Yoshida H
    BJU Int; 2002 Nov; 90(7):748-53. PubMed ID: 12410760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent bladder cancer in aging societies: Importance of major histocompatibility complex class I antigen presentation.
    Wieczorek E; Garstka MA
    Int J Cancer; 2021 Apr; 148(8):1808-1820. PubMed ID: 33105025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
    Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
    J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mouse Norovirus Infection Reduces the Surface Expression of Major Histocompatibility Complex Class I Proteins and Inhibits CD8
    Fritzlar S; Jegaskanda S; Aktepe TE; Prier JE; Holz LE; White PA; Mackenzie JM
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells.
    Imai T; Koyanagi N; Ogawa R; Shindo K; Suenaga T; Sato A; Arii J; Kato A; Kiyono H; Arase H; Kawaguchi Y
    PLoS One; 2013; 8(8):e72050. PubMed ID: 23951282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity.
    Ameres S; Besold K; Plachter B; Moosmann A
    J Immunol; 2014 Jun; 192(12):5894-905. PubMed ID: 24808364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of MAL2 by RAD21 inhibits the expression of MHC-I in immune evasion of endometrial cancer.
    Jin Y; Lu X; Liu Y; Su L; Bao C; Guo H
    Cytotechnology; 2024 Aug; 76(4):465-482. PubMed ID: 38933871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
    Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
    Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macroautophagy Proteins Control MHC Class I Levels on Dendritic Cells and Shape Anti-viral CD8(+) T Cell Responses.
    Loi M; Müller A; Steinbach K; Niven J; Barreira da Silva R; Paul P; Ligeon LA; Caruso A; Albrecht RA; Becker AC; Annaheim N; Nowag H; Dengjel J; García-Sastre A; Merkler D; Münz C; Gannagé M
    Cell Rep; 2016 May; 15(5):1076-1087. PubMed ID: 27117419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.
    Taylor BC; Balko JM
    Front Immunol; 2022; 13():844866. PubMed ID: 35296095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy.
    Ma W; Smith T; Bogin V; Zhang Y; Ozkan C; Ozkan M; Hayden M; Schroter S; Carrier E; Messmer D; Kumar V; Minev B
    J Transl Med; 2011 Mar; 9():34. PubMed ID: 21450109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.
    Bradley SD; Chen Z; Melendez B; Talukder A; Khalili JS; Rodriguez-Cruz T; Liu S; Whittington M; Deng W; Li F; Bernatchez C; Radvanyi LG; Davies MA; Hwu P; Lizée G
    Cancer Immunol Res; 2015 Jun; 3(6):602-9. PubMed ID: 25795007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
    Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
    J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IFN-γ treatment protocol for MHC-I
    Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.